Correction to: Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience

John F. Marcinak (), Melvin S. Munsaka, Paul B. Watkins, Takashi Ohira and Neila Smith
Additional contact information
John F. Marcinak: Takeda Development Center Americas, Inc.
Melvin S. Munsaka: Takeda Development Center Americas, Inc.
Paul B. Watkins: Institute for Drug Safety Sciences, University of North Carolina
Takashi Ohira: Takeda Pharmaceutical Company Limited
Neila Smith: Takeda Development Center Americas, Inc.

Drug Safety, 2018, vol. 41, issue 12, No 23, 1437 pages

Abstract: In the original publication of the article, the ALT and AST values in Fig. 5a–e were capped at 10× ULN, which did not accurately reflect the narrative provided for each case. In this correction, the original Fig. 5a–e (Fig. 1a–e) and the correct Fig. 5a–5e (Fig. 2a–e) are published.

Date: 2018
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://link.springer.com/10.1007/s40264-018-0745-0 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:41:y:2018:i:12:d:10.1007_s40264-018-0745-0

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-018-0745-0

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().